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gδ T cells, a small subset of T lymphocytes, are involved
in innate immunity. It has been demonstrated that gδ T
cells have cytotoxic activities against cells infected with
a variety of viruses. However, there is little evidence
suggesting a cytotoxic activity of gδ T cells against
HTLV-1-infected cells. Therefore, we investigated
whether gδ T cells play a protective role in the defense
against HTLV-1.
Using PBMCs from asymptomatic carriers (ACs) and
HAM/TSP patients, we assayed the frequency of CD3
+Vg9+ (gδ T) cells and the correlation between its fre-
quency and the HTLV-1 load. The frequency of gδ T
cells was significantly decreased in HAM/TSP patients
compared with that in ACs. The frequency of gδ Tc e l l s
was inversely correlated with the proviral load. These
results suggest that gδ T cells have a protective effect on
HTLV-1-infected individuals. Next, CD3+Vg9+ cells and
CD3+Vg9- cells were separated from PBMCs of HTLV-
1-infected persons by FACS and the proviral load of
each population was quantified by real-time PCR. The
proviral load in gδ T cells was markedly lower than that
in CD3+ lacking gδ T cells. Furthermore, we cultured
PBMCs from HTLV-1-infected individuals in the pre-
sence of IL-2 and zoledronate. In some cases, the major-
ity of cells contained in these cultures became gδ T cells
and the proviral load was markedly decreased. The cul-
tured PBMCs showed strong cytotoxic activities against
a HTLV-1-infected cell line as well as an ATL cell line.
T h e s er e s u l t sr a i s et h ep o s s i b i l i t yo fgδ T cell immu-
notherapy in HTLV-1-infected individuals.
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